hat
Abiraterone acetate (INN, USAN, BAN, JAN) (non mak Zytiga, Abiratas, Abretone, Abirapro) se yon inibitè steroidal CYP17A1 ak ekstremite entrodiksyon sentèz endromèn ki itilize nan konbinezon ak prednisone nan kansè nan pwostat metastatik monn ki reziste oswa òmòn-refraktwar kansè nan pwostat) - sa vle di, kansè pwostat pa reponn a privasyon android oswa tretman ak antagonist reseptè antigen.
eng
Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal CYP17A1 inhibitor and by extension androgen synthesis inhibitor which is used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists.